Haematologic toxicity in dogs with mast cell tumours treated with vinblastine/prednisolone chemotherapy with/without radiotherapy. (27th June 2019)

• Record Type: Journal Article
• Authors: Stiborova, K.; Treggiari, E.; Amores‐Fuster, I.; del Busto, I.; Killick, D.; Maddox, T.; Marrington, M.; Mason, S. L.; Blackwood, L.
• Is Part Of: Journal of small animal practice. Volume 60:Number 9(2019)
• Page Start: 534
• Page End: 542
• Publication Date: 2019-06-27
• Subjects: Veterinary medicine -- Periodicals; Veterinary Medicine -- Periodicals; 636.089
• DOI: 10.1111/jsap.13047
• Languages: English
• ISSNs: 0022-4510

Abstract

Abstract : Objectives: To determine whether dogs with surgically excised mast cell tumours receiving a vinblastine/prednisolone chemotherapy protocol in combination with radiation therapy are at greater risk of myelosuppression than patients receiving the chemotherapy protocol alone. Materials and Methods: Retrospective study of clinical records of dogs with mast cell tumours that, subsequent to surgical excision, had received combination vinblasine/prednisolone chemotherapy. Dogs were assigned to two groups: those treated with adjunctive radiotherapy and vinblastine/prednisolone (RT group) and those treated with surgery followed by vinblastine/prednisolone alone (control group). Haematology results were compared between groups. Results: Forty‐three cases and 43 controls of similar breed, age and bodyweight were included. Concurrent radiation and vinblastine chemotherapy did not appear to increase the risk of neutropenia, which was observed in 18.6 and 23.2% of cases in the RT and control groups, respectively. Clinical Significance: Radiation and vinblastine chemotherapy can be safely combined in dogs with mast cell tumours without increasing the risk of clinically important myelosuppression.